Your Partner on the Journey
Innovative strategies that give you a competitive advantage
LSC is a global life sciences consultancy that supports biopharma companies and managers. We partner with our clients to help them gain easier, better and more extended access to treatment for patients who benefit from those breakthroughs. The path to getting a new drug or treatment to market—and to the patients who need it—can be an uphill climb, full of obstacles, potential roadblocks and challenges. At LSC, we have the experience and industry insight it takes to guide our clients through this challenging process, frame and solve problems, and reach their goal: giving patients greater access to treatments and improving their quality of life.
A history of innovation
LSC was founded in 2004 by experienced strategic consulting partners. We have acquired a distinguished portfolio of pharmaceutical and biotech clients, thanks to our commitment, ability to innovate, sound analytical approach and unique insights in the global life sciences sector.
Since then, LSC has proven expertise in both developed and emerging markets. We have established robust practices in the US, the EU, Latin America, the Middle East, Asia and Eastern Europe.
Pierluigi Bruschetta, Managing Partner, Jersey City, NJ, USPierluigi founded and currently leads LSC globally. Prior to founding LSC, Pierluigi held partnership and leadership roles in the pharma and healthcare practices of various global strategic consulting firms (including Gemini Consulting and most recently AT.Kearney). In over 25 years of pharma and healthcare consulting, Pierluigi has advised numerous global product teams at blue-chip top 15 pharmaceutical and medical device companies, as well as CEOs and CCOs of fast-growing US and EU based biotechs. Pierluigi has direct experience in several therapeutic areas, including oncology and hematology, CNS, ophthalmology, CVD and diabetes, inflammatory. He has focused a significant portion of his recent work and applied research on commercial strategy and go-to-market issues of innovative gene and cell therapies worldwide. A father of two children, he holds a B.B.A from University of Palermo, Italy, an M.S. in Cell Biology and Biotechnology from John Hopkins University, an MBA from Bocconi University of Milan and an MPH from Columbia University.
Javier Picó, Partner, Mexico City, Mexico
Javier cofounded the company and has dedicated his entire professional career to healthcare in different landscapes, focusing on developing innovative solutions to help people get access to the best health services available.
Javier has collaborated with governments, health industry associations, hospitals, healthcare providers, medical device companies, diagnosis device companies, health insurance companies and, above all, the pharmaceutical industry, in order to align needs and incentives through innovation. That innovation is backed by a solid quantitative background, with the goal of implementing healthcare policies that are effective in the public sector as well as the private sector.
Javier is an engineer with a master’s degree in applied economics as well as health economics. He is currently developing his doctoral dissertation on “The Value of Health.”
Sheldon Ng, Partner, San Francisco, CA, US
Sheldon is a partner with the global life sciences strategy consulting firm LSC. He leads the San Francisco-based strategy consulting team and brings almost two decades of global experience partnering with both biopharmaceutical and medical technology companies, including emerging and established firms.
Sheldon has functional expertise in asset planning, portfolio management, global operations, launch excellence, lifecycle management and organizational development. His therapeutic expertise includes oncology, immunology, respiratory, ophthalmology, rare diseases and diagnostics.
Sheldon was previously a partner with the life sciences strategy segment at Navigant. Prior to Navigant, he led strategy and analytics at Locust Walk and was a vice president at Health Advances. Sheldon was also in leadership roles at Promidian and IMS Health. Prior to IMS, he worked at Hana Biosciences, Guava Technologies, Exelixis and Chiron in a variety of commercial and scientific roles.
Sheldon has a bachelor’s degree in biological sciences from Cornell University and a Marketing and Healthcare Management MBA from the Kellogg School of Management at Northwestern University.
MARCO SCATIGNA, Scientific Director/Partner, Milan, Italy
Vania Iacuzzi, Principal, Milan, Italy
Vania has been a principal at LSC since 2017. She brings more than 12 years of consulting experience exclusively in the life sciences sector, all of which has been at LSC.
At LSC, she has been instrumental in developing proprietary global practices and perspectives, and has partnered with several biopharmaceutical companies on global strategic engagements. Vania has functional expertise in commercial excellence, market access and patient services. Her therapeutic area expertise includes neurology, onco-hematology, immunology, ophthalmology and rare diseases.
Since 2019, she has also been responsible for consulting excellence within LSC, focusing on recruiting top talent, training and career development, insights management and new perspectives generation. Vania’s long-term commitment to LSC has helped her to support the acceleration of junior consultants’ career paths.
Born in Canada, and a mother of two, Vania earned a master’s degree in management from Bocconi University, as well as a master’s degree in public health (MPH) from Columbia University.
Marco Pedrazzoli, Principal, Zug, Switzerland
Marco joined LSC in 2008, shortly after starting his career in consulting, to specialize in pharmaceuticals and healthcare. He contributed to the growth and internationalization process of the company, rotating across all offices (Europe, Mexico, USA, Gulf) and helping build LSC’s global excellence reputation.
Marco has developed broad global expertise, helping pharma and healthcare system partners to ensure full and timely adoption of innovation—from site readiness for ATMPs, to healthcare systems capacity (for diagnostics and treatment), care pathways, innovative pricing and contracting schemes, and patient/center support programs.
He has specialized in neurosciences, inflammation, hematology and rare diseases, where he is leading a number of international assignments for multiple leading global pharma and biotech firms. He combines a strong quantitative and analytical background with a passion for compelling “story building,” helping professionals in the pharma and healthcare industry visualize and communicate opportunities and challenges.
Marco is Italian, a father of two, and has degrees in economics and business administration from Bocconi University, as well as a master’s degree in public health (MPH) from Columbia University.